(Q42662221)

English

Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule

scientific article published on July 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Voltolini S

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Modena P

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Minale P

3

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Bignardi D

4

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Troise C

5

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Puccinelli P

6

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Parmiani S

7

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

publication date

1 July 2001

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Allergologia et Immunopathologia

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

103-110

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral immunotherapy in birch pollen hay fever

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A computer program based on parallel line assay for analysis of skin tests.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification in mass units of Bet v 1, the main allergen of Betula verrucosa pollen, by a monoclonal antibody based-ELISA

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy with partially purified and standardized tree pollen extracts. III. Specific IgE response to the major allergens of alder, birch and hazel pollen during immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Position paper: Immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979041-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0301-0546(01)79041-6

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42662221&oldid=1964949011"